Opinion

Video

Key End Points in Clinical Trials

Key Takeaways

  • Progression-free survival and overall survival are key endpoints in multiple myeloma trials, crucial for evaluating treatment efficacy.
  • Stringent eligibility criteria in clinical trials may limit their applicability to real-world scenarios, necessitating more inclusive designs.
SHOW MORE

Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.

Video content above is prompted by the following:

  • As a provider, what primary end points in clinical trials are most clinically significant, and how can multiple myeloma clinical trials be changed to be more applicable to or inclusive of real-world scenarios?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.